Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 4
Journal homepage
4
Views
3
CrossRef citations to date
0
Altmetric
CNS Agents

Overview: New Antipsychotic Agents: A Patent Overview — 1991

Joseph A Cipollina Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492
Pages 485-499 | Published online: 02 Mar 2011

References to Primary Literature

  • Levinson DF Pharmacologic treatment of schizophrenia. Clinical Therapeutics 1991 13 326–352.
  • Andersen PH, Nielsen EB Novel approaches to development of antipsychotics. Drug News Perspectives 1991 4 150–157.
  • Davis KL, Kahn RS, Ko G, Davidson M Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiatry 1991 148 1474–1486.
  • Davis KL, Fiori M, Davis BM, Mohs RC, Horvath TB, Davidson M Dopaminergic dysregulation in schizophrenia: A target for new drugs. Drug Dev. Res. 1986 9 71–83.
  • Lowe JA, Seeger TF, Vinick FJ Atypical antipsychotics - recent findings and new perspectives. Med. Res. Rev. 1988 8 475–497.
  • Meltzer HY Novel approaches to the pharmacotherapy of schizophrenia. Drug Dev. Res. 1986 9 23–40.
  • Wise LD, Heffner TG Antipsychotics. Ann. Rep. Med. Chem. 1991 26 53–62 (McCall J) Acad. Press.
  • Abou-Gharbia M, Moyer JA Novel antipsychotic agents. Ann. Rep. Med. Chem. 1991 25 1–10 (Mc Call J) Acad. Press.
  • Bishop JE, Mathis CA, Gerdes JM, Whitney JM, Eaton AM, Mailman RB Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: High-affinity ligands for CNS dopamine D2 receptors. J. Med. Chem. 1991 34 1612–1624.
  • Van Wijngaarden I, Kruse CG, Van der Heyden JAM, Tulpmth M 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2. J. Med. Chem. 1988 31 1934–1940.
  • Van Wijngaarden I, Kruse CG, Van Hes R, van der Heyden JAM, Tulp MthM 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J. Med. Chem. 1987 30 2099–2104.
  • Baindur N, Tran M, Niznik HB, Guan HC, Seeman P, Neumeyer JL (±)-3-Allyl-7-halo-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines as selective high affinity D1 dopamine receptor antagonists: Synthesis and structure-activity relationship. J. Med. Chem. 1992 35 67–72.
  • Pettersson I, Gundertofte K, Palm J, Liljefors T A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D1 receptor activity. J. Med. Chem. 1992 35 502–507.
  • Iorio LC, Cohen M, Coffin VL Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats. J. Pharmacol. Exp. Therap. 1991 258 118–123.
  • Seyfried CA, Boettcher H Central D2-autoreceptor agonists with special reference to indolylbutylamines. Drugs Fut. 1990 15 819–832.
  • Caprathe BW, Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT, Parvez M Dopamine autoreceptor agonists as potential antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.7. Med. Chem. 1991 34 2736–2746.
  • Abou-Gharbia M, Moyer JA, Haskins T 29th Annual Meeting of the American College of Neuropsychopharmacology. Drug News Perspectives 1991 4 124–128.
  • Melzer HY, Matsubara S, Lee J-C The ratios of serotonin and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989 25 390–392.
  • Meltzer HY, Matsubara S, Lee J-C Classification of typical and atypical antipsychotic drugs on the basis of D1, D2 and serotonin2 pKi values. J. Pharmacol. Exp. Therap. 1989 251 238–246.
  • Iqbal N, Asnis GM, Wetzler S, Kay SR, Van Praag HM The role of serotonin in schizophrenia. New findings. Schizophr. Res. 1991 5 181–182.
  • Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S Tiaspirone in schizophrenia. J. Clin. Psychopharmacol. 1987 7 98–101.
  • Jain AK, Kelwala S, Moore N, Gershon S A Controlled clinical trial of tiaspirone in schizophrenia. Int. Clin. Psychopharmacol. 1987 2 129–133.
  • Scott MK, Martin GE, DiStefano DL, Fedde CL, Kukla MJ, Barrett DL, Baldy WJ, Elgin RJ Jr, Kesslick JM, Mathiasen JR, Shank RP, Vaught JL Pyrrole mannich bases as potential antipsychotic agents. J. Med Chem. 1992 35 552–558.
  • Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Krahling H, Naylor RJ, Tomkins DM, Williams TJ The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharm. Bio. Behavior. 1991 40 89–96.
  • Axelsson R, Nilsson A, Christensson E, Bjork A Effects of amperozide in schizophrenia. Psychopharmacol. 1991 104 287–292.
  • Ugedo L, Grenhoff J, Svensson TH Ritanserin, a 5-HT2 receptor antagonist, activates mid brain dopamine neurons by blocking serotonergic inhibition. Psychopharmacol. 1989 98 45–50.
  • Arora RC, Meltzer HY Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural Transm. [GenSect] 1991 85 19–29.
  • Malleron J-L, Comte M-T, Gueremy C, Peyronel JF, Truchon A, Blanchard JC, Doble A, Piot O, Zundel J-L, Huon C, Martin B, Mouton P, Viroulaud A, Allam D, Betschart J Naphthosultam derivatives: A new class of potent and selective 5-HT2 antagonists. J. Med. Chem. 1991 34 2477–2483.
  • Roberston DW, Lacefield WB, Bloomquist W, Pfeifer W, Simon RL, Cohen ML Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: Synthesis and structure-activity relationships. J. Med. Chem. 1992 35 310–319.
  • Cowen PJ Serotonin receptor subtypes: Implications for psychopharmacology. Br. J. Psychiatry 1991 159 suppl 12 7–14.
  • Borison RL, Diamond BI, Dren AT Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacol. Bull. 1991 27 103–106.
  • Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC Sigma receptors: Biology and function. Pharm. Rev. 1990 42 355–402.
  • Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM A ‘glutamatergic hypothesis’ of schizophrenia. Clin. Neuropharmacol. 1989 12 1–13.
  • Carlsson M, Carlsson A Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990 13 272–276.
  • Nair NPV, Lal S, Bloom DM Cholecystokinin and schizophrenia. Prog. Brain Res. 1986 65 237–258.
  • Wang RY Cholecystokinin, dopamine, and schizophrenia: Recent progress and current problems. Ann. NY Acad. Sci. 1988 537 362–379.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.